Symptoms
Adult ADHD: Beyond Childhood
Attention Deficit Hyperactivity Disorder is a common neuropsychiatric condition impacting 4.4% of the adult population age 18-44 according to a recent epidemiological survey. As in childhood, the condition is often marked by challenges with attention, organization and forgetfulness, although adults who were hyperactive as children often grow out of physical hyperactivity. There is evidence that ADHD is associated with poorer outcomes in domestic and occupational endeavors, as well as higher rates of motor vehicle accidents.
2010-2011 Psychiatric Pharmacy Review Course - ACPE Credit Only
The Psychiatric Pharmacy Review Course (Review Course) is an excellent course of study and resource for those seeking a review of psychopharmacology and current standards of care.
Depressive symptoms and APOE polymorphisms in an elderly population-based sample
Aim: Apolipoprotein E (APOE) has been regarded as the principal susceptibility gene linked with Alzheimer's disease, also suggesting a relationship with depression in the elderly population. Thus, the purpose was to investigate the association of APOE polymorphisms with depression in elderly adults.
Methods: APOE polymorphisms were determined in a Mexican population-based sample older than 60 years (n=1566) using 5' exonuclease TaqMan genotyping assays.
Results: The distribution of the APOE allele and genotype frequencies was similar in patients with and without depression.
Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial
Pregabalin (PRE) acts as a presynaptic inhibitor of the release of excessive levels of excitatory neurotransmitters by selectively binding to the 2- subunit of voltage-gated calcium channels. In this randomised, double-blind comparison trial with naltrexone (NAL), we aimed to investigate the efficacy of PRE on alcohol drinking indices. Craving reduction and improvement of psychiatric symptoms were the secondary endpoints. Seventy-one alcohol-dependent subjects were detoxified and subsequently randomised into two groups, receiving 50 mg of NAL or 150—450 mg of PRE.
Seeking Powerpoint presentations
PRN clonidine use in patients treated with diazepam or lorazepam for ethanol and/or benzo withdrawal
difficult case, any suggestions??
Non-Pharmacological Interventions for Schizophrenia
While there is no doubt that medication treatments have demonstrated efficacy for improving clinical symptoms and decreasing rates of relapse for individuals with schizophrenia, many aspects of the illness have not responded or have only partially responded to pharmacotherapy. Multiple psychosocial treatments have been pursued to address these needs. This presentation will focus on two primary types of treatment: Cognitive Behavior Therapy (CBT) and Cognitive Rehabilitation. CBT is designed to decrease the frequency, severity, and the impact on functional outcome of positive symptoms that persist despite adequate medication treatment.
Management of Depression in Post-stroke Patients
Although the prevalence of PSD depends upon whether the patients are examined in community settings or acute hospitals, the mean prevalence of major depressive disorder based on pooled data from the world’s literature is 20% during acute poststroke period for major depression and 19% for minor depression. The diagnosis of depression is based on DSM-IV criteria for major or minor depression. There is relatively little effect of physical illness on the manifestations of depressive symptoms. The major risk factors for developing poststroke depression include severity of impairment in activities of daily living, in cognitive function and in social support.
Delirium and its Management: Focus on Anticholinergics
Delirium is a state of acute confusion resulting from a general medical condition that can last from hours to months, often fluctuates in severity and presentation, and may include a variety of psychiatric symptoms. It is particularly common in the elderly and those with pre-existing cognitive impairment or brain injury. Delirium is a predictor of multiple adverse outcomes, including functional and cognitive decline, increased length of hospitalization, and mortality.